Cara Therapeutics, Inc. (NASDAQ:CARA) Receives $27.84 Consensus Target Price from Analysts

Shares of Cara Therapeutics, Inc. (NASDAQ:CARA) have been given an average recommendation of “Hold” by the five analysts that are covering the company, MarketBeat.com reports. Five analysts have rated the stock with a hold recommendation. The average 12 month price target among analysts that have updated their coverage on the stock in the last year is $27.84.

Separately, StockNews.com initiated coverage on Cara Therapeutics in a research report on Wednesday, January 8th. They set a “sell” rating on the stock.

Cara Therapeutics Stock Up 0.6 %

Shares of NASDAQ:CARA opened at $5.23 on Friday. The company has a market capitalization of $23.92 million, a price-to-earnings ratio of -0.25 and a beta of 0.50. Cara Therapeutics has a 52 week low of $2.71 and a 52 week high of $11.52. The firm has a 50 day moving average of $4.96 and a 200 day moving average of $4.17.

Institutional Trading of Cara Therapeutics

Institutional investors have recently made changes to their positions in the company. Curi RMB Capital LLC purchased a new stake in shares of Cara Therapeutics during the 4th quarter valued at approximately $277,000. Shay Capital LLC purchased a new stake in Cara Therapeutics in the fourth quarter valued at approximately $524,000. XTX Topco Ltd purchased a new stake in Cara Therapeutics in the third quarter valued at approximately $29,000. Rockefeller Capital Management L.P. purchased a new stake in Cara Therapeutics in the fourth quarter valued at approximately $953,000. Finally, FMR LLC raised its position in Cara Therapeutics by 18.5% in the third quarter. FMR LLC now owns 210,312 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 32,789 shares during the period. Hedge funds and other institutional investors own 44.66% of the company’s stock.

About Cara Therapeutics

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.